Dr. Corey sets the overarching vision for the center. To accomplish this he engages internal and external leaders, committees and individuals to help chart the future directions, plans and strategic investments for the center. Planning is achieved through both formal and informal mechanisms. The same approach is applied to evaluation, so that leadership can assess how effectively it is achieving the center's goals and determine whether mid-course changes are needed. This planning and evaluation process has led to timely and successful implementation of new strategies and changes in the organization and direction of cancer research conducted at the Consortium.
The Specific Aims of Planning and Evaluation are to: 1. Provide an effective structure that engages all Consortium partners in planning and evaluation activities such that institutional objectives are well aligned with common Consortium cancer research objectives. 2. Support and maximize the value of internal and external Consortium mechanisms (internal committees and external advisors) to identify areas of greatest strategic importance to the Consortium and their associated resource requirements, and dedicate sufficient leadership and institutional and CCSG funds to achieve measurable success. 3. Provide structure for ongoing evaluation of progress toward Consortium objectives. Major areas of emphasis during the new project period are to further develop solid tumor translational research; improve coordination and consistency of clinical trials support across the center; build biomedical informatics capabilities; expand research in the catchment area and with underserved populations; and build research capacity in cancer health economics, global oncology and obesity. 4. Engage Consortium members in identifying new areas of scientific opportunity, through provision of CCSG and other funds to support scientific symposia and workshops on emerging research areas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617703
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Herman, Daniel S; Smith, Christina; Liu, Chang et al. (2018) Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog. J Mol Diagn 20:512-521
Birnbaum, Jeanette K; Duggan, Catherine; Anderson, Benjamin O et al. (2018) Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study. Lancet Glob Health 6:e885-e893
Partridge, Emma K; Neuhouser, Marian L; Breymeyer, Kara et al. (2018) Comparison of Nutrient Estimates Based on Food Volume versus Weight: Implications for Dietary Assessment Methods. Nutrients 10:
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Kuzma, Jessica N; Cromer, Gail; Hagman, Derek K et al. (2018) Consuming glucose-sweetened, not fructose-sweetened, beverages increases fasting insulin in healthy humans. Eur J Clin Nutr :
Neumeyer, Sonja; Banbury, Barbara L; Arndt, Volker et al. (2018) Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. Br J Cancer 118:1639-1647
Puré, Ellen; Hingorani, Sunil R (2018) Mesenchymal Cell Plasticity and Perfidy in Epithelial Malignancy. Trends Cancer 4:273-277
Yu, Hsiang; Cheng, Yu-Jen; Wang, Ching-Yun (2018) Methods for multivariate recurrent event data with measurement error and informative censoring. Biometrics 74:966-976
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Barault, Ludovic; Amatu, Alessio; Siravegna, Giulia et al. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67:1995-2005

Showing the most recent 10 out of 1267 publications